Open AccessAllele-Specific Recombinase Polymerase Amplification to Detect Sickle Cell Disease in Low-Resource Settings
Author(s) -
Mary E. Natoli,
Megan Chang,
Kathryn Kundrod,
Jackson B. Coole,
Gladstone Airewele,
Venée N. Tubman,
Rebecca RichardsKortum
Publication year - 2021
Publication title -
analytical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.117
H-Index - 332
eISSN - 1520-6882
pISSN - 0003-2700
DOI - 10.1021/acs.analchem.0c04191
Subject(s) - recombinase polymerase amplification , genotyping , globin , microbiology and biotechnology , chemistry , fluorometer , nucleic acid , point mutation , allele , point of care testing , polymerase chain reaction , mutation , genotype , immunology , biology , hemoglobin , gene , biochemistry , fluorescence , physics , quantum mechanics
Sickle cell disease (SCD) is a group of common, life-threatening disorders caused by a point mutation in the β globin gene. Early diagnosis through newborn and early childhood screening, parental education, and preventive treatments are known to reduce mortality. However, the cost and complexity of conventional diagnostic methods limit the feasibility of early diagnosis for SCD in resource-limited areas worldwide. Although several point-of-care tests are commercially available, most are antibody-based tests, which cannot be used in patients who have recently received a blood transfusion. Here, we describe the development of a rapid, low-cost nucleic acid test that uses real-time fluorescence to detect the point mutation encoding hemoglobin S (HbS) in one round of isothermal recombinase polymerase amplification (RPA). When tested with a set of clinical samples from SCD patients and healthy volunteers, our assay demonstrated 100% sensitivity for both the β A globin and β S globin alleles and 94.7 and 97.1% specificities for the β A globin allele and β S globin allele, respectively ( n = 91). Finally, we demonstrate proof-of-concept sample-to-answer genotyping of genomic DNA from capillary blood using an alkaline lysis procedure and direct input of diluted lysate into RPA. The workflow is performed in <30 min at a cost of <$5 USD on a commercially available benchtop fluorimeter and an open-source miniature fluorimeter. This study demonstrates the potential utility of a rapid, sample-to-answer nucleic acid test for SCD that may be implemented near the point of care and could be adapted to other disease-causing point mutations in genomic DNA.